{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:37:55Z","timestamp":1790127475601,"version":"4.0.1"},"reference-count":62,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,8]],"date-time":"2024-01-08T00:00:00Z","timestamp":1704672000000},"content-version":"vor","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011821","name":"Kingdom of Saudi Arabia Ministry of Education","doi-asserted-by":"publisher","award":["IFKSURC-1-0509"],"award-info":[{"award-number":["IFKSURC-1-0509"]}],"id":[{"id":"10.13039\/501100011821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.heliyon.2024.e24406","type":"journal-article","created":{"date-parts":[[2024,1,11]],"date-time":"2024-01-11T23:31:59Z","timestamp":1705015919000},"page":"e24406","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Calotropis procera: A double edged sword against glioblastoma, inhibiting glioblastoma cell line growth by targeting histone deacetylases (HDAC) and angiogenesis"],"prefix":"10.1016","volume":"10","author":[{"given":"Shamsa Hilal","family":"Saleh Alanazi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9891-2443","authenticated-orcid":false,"given":"Muhammad","family":"Farooq Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anas M.","family":"Alazami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Almohannad","family":"Baabbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Ahmed Wadaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00005-012-0203-0","article-title":"Glioblastoma, a brief review of history, molecular genetics, animal models and novel therapeutic strategies","volume":"61","author":"Agnihotri","year":"2013","journal-title":"Arch. Immunol. Ther. Exp."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24406_bib2","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"Ca-Cancer J Clin"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24406_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/life11050421","article-title":"Current status of brain tumor in the Kingdom of Saudi Arabia and application of nanobiotechnology for its treatment: a comprehensive review","volume":"11","author":"Moin","year":"2021","journal-title":"Life"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24406_bib4","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1007\/s12035-020-01892-8","article-title":"Tumor development and angiogenesis in adult brain tumor: glioblastoma","volume":"57","author":"Ahir","year":"2020","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.heliyon.2024.e24406_bib5","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/j.jconrel.2023.02.002","article-title":"Gastrointestinally absorbable lactoferrin-heparin conjugate with anti-angiogenic activity for treatment of brain tumor","volume":"355","author":"Hwang","year":"2023","journal-title":"J. Contr. Release"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e24406_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12101625","article-title":"Glioblastoma-specific strategies of vascularization: implications in anti-angiogenic therapy resistance","volume":"12","author":"Buccarelli","year":"2022","journal-title":"J. Personalized Med."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24406_bib7","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41571-020-00447-z","article-title":"EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood","volume":"18","author":"Weller","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1159\/000488258","article-title":"Anti-angiogenics: their role in the treatment of glioblastoma","volume":"41","author":"Winkler","year":"2018","journal-title":"Oncol. Res. Treat."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24406_bib9","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11060-017-2477-x","article-title":"The role of bevacizumab in the treatment of glioblastoma","volume":"133","author":"Diaz","year":"2017","journal-title":"J. Neuro Oncol."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib10","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1634\/theoncologist.2014-0330","article-title":"Practical management of bevacizumab-related toxicities in glioblastoma","volume":"20","author":"Brandes","year":"2015","journal-title":"Oncol."},{"key":"10.1016\/j.heliyon.2024.e24406_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hermed.2017.03.003","article-title":"Broad spectrum targeting of tumor vasculature by medicinal plants: an updated review","volume":"9","author":"Yehya","year":"2017","journal-title":"J. Herb. Med."},{"key":"10.1016\/j.heliyon.2024.e24406_bib12","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fonc.2017.00045","article-title":"Therapeutic targeting of histone modifications in adult and pediatric high-grade glioma","volume":"7","author":"Williams","year":"2017","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib13","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13046-020-01643-6","article-title":"The application of histone deacetylases inhibitors in glioblastoma","volume":"39","author":"Chen","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24406_bib14","doi-asserted-by":"crossref","first-page":"18577","DOI":"10.18632\/oncotarget.14612","article-title":"Advances in epigenetic glioblastoma therapy","volume":"8","author":"Lee","year":"2017","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib15","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00432-018-2800-8","article-title":"Histone deacetylase inhibitor ITF2357 (givinostat) reverts transformed phenotype and counteracts stemness in in vitro and in vivo models of human glioblastoma","volume":"145","author":"Marampon","year":"2019","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"Pt 3","key":"10.1016\/j.heliyon.2024.e24406_bib16","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1042\/bj20021321","article-title":"Histone deacetylases (HDACs): characterization of the classical HDAC family","volume":"370","author":"de Ruijter","year":"2003","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib17","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1016\/j.jksus.2020.03.017","article-title":"The phytochemical screening and antiangiogenic activity of audthan al himar (Moricandia sinaica Boiss.) extracts in zebrafish embryos and human umbilical vein endothelial cells","volume":"32","author":"Farooq","year":"2020","journal-title":"J. King Saud Univ. Sci."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24406_bib18","doi-asserted-by":"crossref","first-page":"a006684","DOI":"10.1101\/cshperspect.a006684","article-title":"Vascular development in the zebrafish","volume":"2","author":"Gore","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.heliyon.2024.e24406_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1160616","article-title":"An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer","volume":"14","author":"Rajkovic","year":"2023","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24406_bib20","first-page":"374","article-title":"Pharmacognostic study of Calotropis procera (Aiton) W.T. Aiton root and stem","volume":"13","author":"Tripathi","year":"2022","journal-title":"Indian J Nat Prod Re"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/s43094-023-00467-3","article-title":"A systematic review on the biological evaluation of Calotropis procera (Aiton) Dryand","volume":"9","author":"Dogara","year":"2023","journal-title":"Futur J Pharm Sci"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e24406_bib22","first-page":"7604","article-title":"Breakpoint junctions of chromosome 9p deletions in two human glioma cell lines","volume":"14","author":"Pomykala","year":"1994","journal-title":"Mol. Cell Biol."},{"issue":"354","key":"10.1016\/j.heliyon.2024.e24406_bib23","doi-asserted-by":"crossref","first-page":"354re3","DOI":"10.1126\/scitranslmed.aaf6853","article-title":"Origin of the U87MG glioma cell line: good news and bad news","volume":"8","author":"Allen","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib24","article-title":"Gene expression profiling of glioblastoma cell lines depending on TP53 status after tumor-treating fields (TTFields) treatment","volume":"10","author":"Lee","year":"2020","journal-title":"Sci Rep-Uk"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1002\/cam4.219","article-title":"U-251 revisited: genetic drift and phenotypic consequences of long-term cultures of glioblastoma cells","volume":"3","author":"Torsvik","year":"2014","journal-title":"Cancer Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib26","first-page":"206","article-title":"Cytotoxic effect of boron application on glioblastoma cells","volume":"31","author":"Aydin","year":"2021","journal-title":"Turk Neurosurg"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.ajhg.2016.02.010","article-title":"Mutations in SMG9, encoding an essential component of nonsense-mediated decay machinery, cause a multiple congenital anomaly syndrome in humans and mice","volume":"98","author":"Shaheen","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.heliyon.2024.e24406_bib28","series-title":"2D Minimal Bounding Box","author":"diener","year":"2023"},{"key":"10.1016\/j.heliyon.2024.e24406_bib29","series-title":"The Zebrafish Book: A Guide for the Laboratory Use of Zebrafish (Danio Rerio)","author":"Westerfield","year":"1995"},{"key":"10.1016\/j.heliyon.2024.e24406_bib30","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.reprotox.2011.06.121","article-title":"Zebrafish embryos as an alternative to animal experiments\u2014a commentary on the definition of the onset of protected life stages in animal welfare regulation","volume":"33","author":"Str\u00e4hle","year":"2011","journal-title":"Reprod. Toxicol."},{"issue":"12","key":"10.1016\/j.heliyon.2024.e24406_bib31","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.2174\/0929867043365099","article-title":"Trichostatin A - like hydroxamate histone deacetylase inhibitors as therapeutic agents: toxicological point of view","volume":"11","author":"Vanhaecke","year":"2004","journal-title":"Curr. Med. Chem."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e24406_bib32","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/aja.1002030302","article-title":"Stages of embryonic development of the zebrafish","volume":"203","author":"Kimmel","year":"1995","journal-title":"Dev. Dynam."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24406_bib33","doi-asserted-by":"crossref","first-page":"17489","DOI":"10.18632\/aging.203238","article-title":"HDAC inhibitor Trichostatin A suppresses adipogenesis in 3T3-L1 preadipocytes","volume":"13","author":"Lv","year":"2021","journal-title":"Aging (Albany NY)"},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24406_bib34","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0301-472X(02)00837-8","article-title":"The protein tyrosine kinase inhibitor SU5614 inhibits VEGF-induced endothelial cell sprouting and induces growth arrest and apoptosis by inhibition of c-kit in AML cells","volume":"30","author":"Spiekermann","year":"2002","journal-title":"Exp. Hematol."},{"issue":"13","key":"10.1016\/j.heliyon.2024.e24406_bib35","doi-asserted-by":"crossref","first-page":"8596","DOI":"10.1021\/acs.jmedchem.1c01946","article-title":"Glioblastoma: current status, emerging targets, and recent advances","volume":"65","author":"Thakur","year":"2022","journal-title":"J. Med. Chem."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e24406_bib36","first-page":"2407","article-title":"Synergistic killing of glioblastoma stem-like cells by bortezomib and HDAC inhibitors","volume":"32","author":"Asklund","year":"2012","journal-title":"Anticancer Res."},{"key":"10.1016\/j.heliyon.2024.e24406_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.phytochem.2021.112951","article-title":"Cytotoxic cardenolides from Calotropis gigantea","volume":"192","author":"He","year":"2021","journal-title":"Phytochemistry"},{"issue":"16","key":"10.1016\/j.heliyon.2024.e24406_bib38","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.3748\/wjg.v12.i16.2517","article-title":"Anticancer and cytotoxic properties of the latex of Calotropis procera in a transgenic mouse model of hepatocellular carcinoma","volume":"12","author":"Choedon","year":"2006","journal-title":"World J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e24406_bib39","first-page":"343","article-title":"Anti-tumor studies with extracts of Calotropis procera (Ait.) R.Br. root employing Hep 2 cells and their possible mechanism of action","volume":"47","author":"Mathur","year":"2009","journal-title":"Indian J. Exp. Biol."},{"issue":"23","key":"10.1016\/j.heliyon.2024.e24406_bib40","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1080\/14786419.2014.1001386","article-title":"Calotropis procera extract induces apoptosis and cell cycle arrest at G2\/M phase in human skin melanoma (SK-MEL-2) cells","volume":"29","author":"Joshi","year":"2015","journal-title":"Nat. Prod. Res."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e24406_bib41","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1016\/j.tiv.2007.05.007","article-title":"In vitro cytotoxicity against different human cancer cell lines of laticifer proteins of Calotropis procera (Ait.) R","volume":"21","author":"Soares de Oliveira","year":"2007","journal-title":"Br, Toxicol In Vitro"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24406_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2023.e16706","article-title":"Potential anticancer properties of calotropis procera: an investigation on breast and colon cancer cells","volume":"9","author":"Bou Malhab","year":"2023","journal-title":"Heliyon"},{"issue":"S1","key":"10.1016\/j.heliyon.2024.e24406_bib43","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.2022.36.S1.R4424","article-title":"Ethanolic extract of calotropis procera exhibits antitumor effects on human breast and colon cancer cells via cell cycle arrest","volume":"36","author":"Abu-Gharbieh","year":"2022","journal-title":"Faseb. J."},{"issue":"10","key":"10.1016\/j.heliyon.2024.e24406_bib44","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27103123","article-title":"Antimicrobial, antigenotoxicity, and characterization of calotropis procera and its rhizosphere-inhabiting actinobacteria: in vitro and in vivo studies","volume":"27","author":"Saddiq","year":"2022","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib45","article-title":"Acute and subacute toxicity study of ethanolic extract of Calotropis procera (Aiton) Dryand flower in Swiss albino mice","volume":"2","author":"Kumar","year":"2022","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.toxicon.2010.11.007","article-title":"Clinical and pathological effects of Calotropis procera exposure in sheep and rats","volume":"57","author":"de Lima","year":"2011","journal-title":"Toxicon"},{"issue":"23","key":"10.1016\/j.heliyon.2024.e24406_bib47","doi-asserted-by":"crossref","first-page":"19469","DOI":"10.18632\/oncotarget.3625","article-title":"Curcumin inhibits angiogenesis and improves defective hematopoiesis induced by tumor-derived VEGF in tumor model through modulating VEGF-VEGFR2 signaling pathway","volume":"6","author":"Fu","year":"2015","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib48","first-page":"5","article-title":"Calotropis procera root extracts block VEGF-induced angiogenesis: quantitative analysis","volume":"55","author":"Mathur","year":"2011","journal-title":"Indian J. Physiol. Pharmacol."},{"key":"10.1016\/j.heliyon.2024.e24406_bib49","series-title":"xPharm: the Comprehensive Pharmacology Reference","first-page":"1","article-title":"Semaxinib","author":"Scholar","year":"2007"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24406_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11060747","article-title":"Histone deacetylase inhibitors impair vasculogenic mimicry from glioblastoma cells","volume":"11","author":"Pastorino","year":"2019","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib51","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1177\/147323001003800416","article-title":"Expression of activin A and follistatin in glioblastoma and their effects on U87 in vitro","volume":"38","author":"Zhang","year":"2010","journal-title":"J. Int. Med. Res."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib52","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3892\/ijo.2020.5058","article-title":"Activin A triggers angiogenesis via regulation of VEGFA and its overexpression is associated with poor prognosis of oral squamous cell carcinoma","volume":"57","author":"Ervolino De Oliveira","year":"2020","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib53","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/0049-3848(87)90349-5","article-title":"Cloning and expression of human tissue factor cDNA","volume":"48","author":"Fisher","year":"1987","journal-title":"Thromb. Res."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib54","doi-asserted-by":"crossref","first-page":"e1699","DOI":"10.1002\/cnr2.1699","article-title":"Systematic study of tissue factor expression in solid tumors","volume":"6","author":"de Bono","year":"2023","journal-title":"Cancer Reports"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib55","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/bcr1871","article-title":"Tissue factor, angiogenesis and tumour progression","volume":"10","author":"Bluff","year":"2008","journal-title":"Breast Cancer Res."},{"issue":"22","key":"10.1016\/j.heliyon.2024.e24406_bib56","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.21037\/atm-22-5067","article-title":"Tissue factor as a new target for tumor therapy\u2014killing two birds with one stone: a narrative review","volume":"10","author":"Li","year":"2022","journal-title":"Ann. Transl. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e24406_bib57","first-page":"615","article-title":"Mechanisms and clinical significance of histone deacetylase inhibitors: epigenetic glioblastoma therapy","volume":"35","author":"Lee","year":"2015","journal-title":"Anticancer Res."},{"issue":"6","key":"10.1016\/j.heliyon.2024.e24406_bib58","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24061047","article-title":"Role of natural products in modulating histone deacetylases in cancer","volume":"24","author":"Merarchi","year":"2019","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e24406_bib59","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","article-title":"Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends","volume":"28","author":"Nepali","year":"2021","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e24406_bib60","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a018713","article-title":"Erasers of histone acetylation: the histone deacetylase enzymes","volume":"6","author":"Seto","year":"2014","journal-title":"Cold Spring Harbor Perspect. Biol."},{"key":"10.1016\/j.heliyon.2024.e24406_bib61","article-title":"Comprehensive analysis of the differential expression and prognostic value of histone deacetylases in glioma","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.heliyon.2024.e24406_bib62","article-title":"Comprehensive analysis of the differential expression and prognostic value of histone deacetylases in glioma","volume":"10","author":"Li","year":"2022","journal-title":"Front. Cell Dev. Biol."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024004377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024004377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T08:22:18Z","timestamp":1783930938000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024004377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2405844024004377"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24406","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calotropis procera: A double edged sword against glioblastoma, inhibiting glioblastoma cell line growth by targeting histone deacetylases (HDAC) and angiogenesis","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e24406","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e24406"}}